title: [Contrast-enhanced MRT of malignant melanoma of the uvea].
abstract: Twenty-one patients with malignant melanoma of the uvea or iris, some with intra-ocular bleeding, were examined by MRT before and after the administration of Gd/DTPA. In 13 patients, several examinations were performed over a period of 1.5 to 20 months after irradiation of the melanoma. After Gd-DTPA there was an average increase of 13% in the signal intensity from all non-irradiated melanomas (17 cases). Three months following radiation therapy, there was an average increase in signal intensity after Gd-DTPA of 65.7%, and after seven months of 100%. Amelanotic melanomas (two cases) showed a primary increase in intensity of 100%. Two melanomas of the iris were demonstrated by sonography; of these, only one could be shown with certainty by MRT. Small tumours and tumour residues after irradiation were better defined after contrast. In the presence of suspected intra-ocular bleeding, the examination should always be performed after the administration of Gd-DTPA.
authors.affiliation: Klinik für Radiologische Diagnostik der Rheinisch Westfälischen Technischen Hochschule Aachen.
authors.forename: G
authors.initials: G
authors.lastname: Adam
authors.forename: M
authors.initials: M
authors.lastname: Brab
authors.forename: K
authors.initials: K
authors.lastname: Bohndorf
authors.forename: K C
authors.initials: KC
authors.lastname: Klose
authors.forename: R W
authors.initials: RW
authors.lastname: Günther
mesh_terms: D000328:Adult; D000368:Aged; D003287:Contrast Media; D005260:Female; D005682:Gadolinium; D019786:Gadolinium DTPA; D006801:Humans; D015811:Iris Neoplasms / Q000175:diagnosis; D008279:Magnetic Resonance Imaging; D008297:Male; D008545:Melanoma / Q000175:diagnosis*; D008875:Middle Aged; D009942:Organometallic Compounds; D004369:Pentetic Acid; D014604:Uveal Neoplasms / Q000175:diagnosis*
chemical_list: D003287:Contrast Media; D009942:Organometallic Compounds; D004369:Pentetic Acid; D005682:Gadolinium; D019786:Gadolinium DTPA
vernacular_title: Kontrastmittelunterstützte MRT maligner Aderhautmelanome.